National Academy of Sciences | 150 Year Anniversary

Questions? Call 800-624-6242

| Items in cart [0]

The National Academies Press

Rights & Permissions

topleft topright

New Vaccine Development: Establishing Priorities: Volume I, Diseases of Importance in the United States (1985)
Board on Population Health and Public Health Practice (BPH)

Citation Manager

. "Appendix T: Additional Sources of Advice to the Committee." New Vaccine Development: Establishing Priorities: Volume I, Diseases of Importance in the United States. Washington, DC: The National Academies Press, 1985.

Please select a format:

BibTeX EndNote RefMan


Page
450
bottomleft bottomright

The following HTML text is provided to enhance online readability. Many aspects of typography translate only awkwardly to HTML. Please use the page image as the authoritative form to ensure accuracy.


New Vaccine Development Establishing Priorities, Volume I: Diseases of Importance in the United States

Appendix T
ADDITIONAL SOURCES OF ADVICE TO THE COMMITTEE

Charles A.Alford, The University of Alabama in Birmingham.

William P.Allen, National Institutes of Health, Bethesda, Md.

Miriam J.Alter, The Centers for Disease Control, Atlanta, Ga.

Larry J.Anderson, The Centers for Disease Control, Atlanta, Ga.

Porter W.Anderson, The university of Rochester Medical Center

Bascom Anthony, Harbor-UCLA Medical Center, Torrance, Calif.

Carol J.Baker, Baylor College of Medicine, Houston, Tex.

William H.Bancroft, Walter Reed Army Medical Center, Wash., D.C.

John G.Bartlett, The Johns Hopkins University School of Medicine, Baltimore, Md.

Joel B.Baseman, The University of Texas Health Science Center at San Antonio.

Edwin H.Beachey, Veterans Administration Medical Center, Memphis, Tenn.

Alan L.Bisno, University of Tennessee Center for the Health Sciences, Memphis.

Edward W.Brink, The Centers for Disease Control, Atlanta, Ga.

Charles Brinton, University of Pittsburgh, Pa.

Claire V.Broome, The Centers for Disease Control, Atlanta, Ga.

Philip A.Brunell, The University of Texas Health Science Center at San Antonio.

Yvonne J.Bryson, UCLA School of Medicine, Torrance.

Thomas M.Buchanan, Seattle Public Health Hospital, Wash.

James P.Carlos, National Institutes of Health, Bethesda, Md.

Willard Cates, Jr., The Centers for Disease Control, Atlanta, Ga.

James D.Cherry, University of California at Los Angeles School of Medicine.

Wallace A.Clyde, Jr., The University of North Carolina at Chapel Hill.

Stephen L.Cochi, The Centers for Disease Control, Atlanta, Ga.

Michael F.Cole, National Institutes of Health, Bethesda, Md.

Lawrence Corey, University of Washington, Seattle.

Rebecca A.Cox, San Antonio State Chest Hospital, Tex.

Floyd W.Denny, The University of North Carolina at Chapel Hill.

Jules L.Dienstag, Harvard Medical School, Boston, Mass.

Hugh C.Dillon, Jr., The University of Alabama in Birmingham.

R.Gordon Douglas, Jr., The New York Hospital-Cornell Medical Center, N.Y.

Page
450
Front Matter (R1-R14)
1. Summary (1-16)
2. Priority Setting for Health Related Investments: A Review of Methods (17-27)
3. Overview of the Analytic Approach (28-38)
4. Comparison of Disease Burdens and Costs (39-58)
5. Predictions on Vaccine Development (59-66)
6. Assessing the Likely Utilization of New Vaccines (67-91)
7. Calculation and Comparison of the Health Benefits and Costs Associated with Candidate Vaccines (92-120)
8. Additional Issues in the Selection of Priorities for Accelerated Vaccine Development (121-126)
9. Findings, Conclusions, and Recommendations (127-148)
Appendix A: Some Examples of the Application of Project Selection Method (149-152)
Appendix B: Pathogenic Agents for Which Accelerated Vaccine Development Does Not Appear Appropriate (153-170)
Appendix C: Prospects for Immunizing Against Bordetella pertussis (171-182)
Appendix D: Prospects for Immunizing Against Coccidioidomycosis (183-197)
Appendix E: Prospects for Immunizing Against Cytomegalovirus (198-234)
Appendix F: Prospects for Immunizing Against Hemophilus influenzae type b (235-251)
Appendix G: Prospects for Immunizing Against Hepatitis A Virus (252-260)
Appendix H: Prospects for Immunizing Against Hepatitis B Virus (261-279)
Appendix I: Prospects for Immunizing Against Herpes Simplex Viruses 1 and 2 (280-312)
Appendix J: Prospects for Immunizing Against Herpesvirus varicellae (313-341)
Appendix K: Prospects for Immunizing Against Influenza Viruses A and B (342-364)
Appendix L: Prospects for Immunizing Against Neisseria gonorrhoeae (365-384)
Appendix M: Prospects for Immunizing Against Parainfluenza Viruses (385-396)
Appendix N: Prospects for Immunizing Against Respiratory Syncytial Virus (397-409)
Appendix O: Prospects for Immunizing Against Rotavirus (410-423)
Appendix P: Prospects for Immunizing Against Streptococcus group B (424-439)
Appendix Q: Questionnaire for Assessing Morbidity-Mortality Trade-Offs (440-443)
Appendix R: Technical Notes (444-444)
Appendix S: Biographical Notes on Committee Members (445-449)
Appendix T: Additional Sources of Advice to the Committee (450-452)
Index (453-458)

Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole.
Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.

Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.

OCR for page 450

OCR for page 451

OCR for page 452